Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
about
Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndromeAnalysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry.Measurement of serum estrogen and estrogen metabolites in pre- and postmenopausal women with osteoarthritis using high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays.Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndromeAnalysis of estrogens in serum and plasma from postmenopausal women: past present, and futureMechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.Assessing individual risk for breast cancer: role of oestrogens and androgensDevelopment of a high sensitivity, nested Q-PCR assay for mouse and human aromataseComparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens.Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.Tandem mass spectrometry as a novel tool for elucidating pituitary-thyroid relationships.Simultaneous Measurement of 17β-Estradiol, 17α-Estradiol and Estrone by GC-Isotope Dilution MS/MS.Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumLC-MS/MS in the Clinical Laboratory - Where to From Here?Quantification of neurosteroids during pregnancy using selective ion monitoring mass spectrometry.Improved profiling of estrogen metabolites by orbitrap LC/MS.Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients.Barriers to effective treatment of vaginal atrophy with local estrogen therapy.Challenges to the measurement of estradiol: an endocrine society position statementCorrelations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populationsSteroid hormone analysis by tandem mass spectrometry.Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.Aromatase Inhibition Reduces Insulin Sensitivity in Healthy MenTwelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.Predictors of recovery of ovarian function during aromatase inhibitor therapy.Liquid chromatography/mass spectrometry of pre-ionized Girard P derivatives for quantifying estrone and its metabolites in serum from postmenopausal womenAnalysis of steroidal estrogens as pyridine-3-sulfonyl derivatives by liquid chromatography electrospray tandem mass spectrometry.The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistancePrediction of postchemotherapy ovarian function using markers of ovarian reserve.Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.Bringing GC-MS profiling of steroids into clinical applications.Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism.Interfacial nano-biosensing in microfluidic droplets for high-sensitivity detection of low-solubility molecules.Simultaneous profiling of 17 steroid hormones for the evaluation of endocrine-disrupting chemicals in H295R cells.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
P2860
Q30353094-6D29EF86-17DE-46B6-9D12-061CF2898C1BQ30358054-18C85419-3D26-4312-B816-49902E3B26CAQ30360030-CE990954-500F-4184-B3A3-A585E420058BQ30418048-D7863050-B21A-440F-865E-07BC46BB5D4CQ30424208-D97C7AFF-DCB2-4D6D-8C3B-9B0BC3FA1268Q30424276-B063CC31-89E2-466F-B005-82A363E586A7Q30432877-89A7847D-D164-466F-A762-6523F1ADD890Q30436239-AE47CF87-68F4-46F7-A3C6-26F3F0F30D33Q30440472-37FB55F4-52DA-4DAD-9039-74A129196F11Q30440930-44872C3C-9D7C-47D7-AD6D-A7100C694469Q33720606-F7F009B7-A5E3-4AC5-AC42-73270799B719Q33777302-EE5F0BD4-A497-47F7-9E74-81A47D1F81C2Q33801438-08708F91-9B2A-4C9B-88A0-E6FCD51E6DAEQ33980175-9369D05B-492C-483C-9264-6E7C381B5AFAQ34020925-7FCC3E6F-2706-4C15-B000-D2974CD16137Q34592879-3C85170D-5D8E-47A6-9FED-0DCD9CED2192Q34640830-BA4BB4CD-3544-4B28-8B3E-97CB0E461F64Q35070885-8CA70AD9-1C7A-40B6-9846-D1C48280502FQ35655848-ED70BDB5-86ED-4AFF-A7E9-D430A3B5467AQ36689257-0BFCDC9B-3F8C-4FD1-88E8-5F4101702FF2Q36702052-0D69F060-A0B1-43E1-B176-B181440EF6EFQ36736507-4AC26818-1140-419E-8524-D41A09A9FCE1Q36787933-5808B4A0-6DE8-4797-BED0-50BDCF3A05B6Q36789978-BA85E3CB-15D0-4348-80E2-96B1FA6E9D7EQ36884366-61753989-E319-4CD0-B907-CDA5C9ACA141Q36911503-CA0A3A75-9097-49FF-B718-D11587F38DADQ36915182-FE6DFA81-02A5-4BBC-B595-00EF29AE99AEQ36927755-005910E4-4EC2-4E2C-BDF5-BE4B84BB29ECQ37032856-271B664D-7D05-424D-9BCE-9B49120A9F29Q37066145-4F03B461-804F-43FB-86E4-86E8EF7A4225Q37174336-07759606-943D-4D31-8FE6-FBCD237C0ECEQ37308154-7268BC67-96A8-4D18-8F89-EE301002A4A6Q37519037-2B2A0476-0B5E-48F8-9CF8-544BE4C8BB63Q37633691-351111B3-269E-47D1-8553-A2372EAB7829Q38121156-888518D3-5D08-4BB8-9063-DFE9CC6CC64EQ38223309-1D2318FB-C817-471D-924E-AC34579DE4B4Q38494456-71646898-48E2-4088-9A48-A3285BCC67A1Q38569998-311761FC-A5DC-42CB-9B5F-22ECE4B8E3A0Q38727473-A6E6D32C-2CDE-4856-9C1B-E3DECC261656Q38739248-137A2DC0-8A65-4C8C-B17D-D6A9CFBCAD47
P2860
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@ast
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@en
type
label
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@ast
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@en
prefLabel
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@ast
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@en
P2093
P1433
P1476
Superiority of gas chromatogra ...... f aromatase inhibitor therapy.
@en
P2093
D Blanchett
J Settlage
Lawrence Demers
Paul E Goss
Peter Langecker
Richard J Santen
Shuping Wang
Susan Ohorodnik
P304
P356
10.1016/J.STEROIDS.2007.05.003
P577
2007-05-21T00:00:00Z